A wave of fresh research is reshaping how doctors treat newly diagnosed multiple myeloma (NDMM). A large Chinese multicenter trial found that the drug combo DVd (daratumumab, bortezomib, dexamethasone) kept patients progression‑free for 12 months at a higher rate than the older VRd regimen, suggesting a new standard of care. Meanwhile, the long‑term MAIA study confirmed that adding daratumumab to Rd (lenalidomide, dexamethasone) improves overall survival and offers a safer side‑effect profile for patients who can’t undergo transplant. Researchers in Sichuan linked a steeper drop in kidney function during the first year to higher mortality, highlighting the need for early kidney monitoring. Cutting‑edge risk tools are also emerging: circulating tumor cells can spot hidden high‑risk disease beyond traditional genetics, and measurable residual disease (MRD) testing now guides personalized therapy choices. Immunotherapy is advancing fast—bispecific antibodies and CAR‑T cells targeting BCMA or GPRC5D show promise, with bispecifics offering off‑the‑shelf convenience and fewer acute toxicities. A phase‑II trial combining the BiRD regimen with BCMA CAR‑T showed longer hospital‑free periods without sacrificing efficacy. Finally, a new dose‑simulation study of mabelantamab helps fine‑tune dosing for better eye safety, and a Chinese trial (PVd vs. Vd) provides the first solid data for NDMM patients with kidney problems. Together, these findings point to more effective, personalized, and safer treatment pathways for multiple myeloma.
Read more